Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
29.37
Nov 13 • 3:59 PM ET Dollar change+0.50 Percentage change(1.73%)
Aftermarket Close
29.37
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
1.25B
Enterprise Value
1.71B
Income
98.96M
Sales
745.79M
Book/sh
19.10
Cash/sh
5.46
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
1976
IPO
Jun 25, 2014
P/E
13.27
Forward P/E
8.76
PEG
2.74
P/S
1.68
P/B
1.54
P/C
5.37
P/FCF
9.01
EV/EBITDA
8.29
EV/Sales
2.29
Quick Ratio
2.36
Current Ratio
3.32
Debt/Eq
0.85
LT Debt/Eq
0.84
Option/Short
Yes / Yes
EPS (ttm)
2.21
EPS next Y
3.35
EPS next Q
0.79
EPS this Y
-1.60%
EPS next Y
4.85%
EPS next 5Y
3.20%
EPS past 3/5Y
5.29% 134.65%
Sales past 3/5Y
12.99% 15.53%
EPS Y/Y TTM
-4.26%
Sales Y/Y TTM
3.11%
EPS Q/Q
139.24%
Sales Q/Q
8.22%
Insider Own
27.35%
Insider Trans
-0.53%
Inst Own
67.56%
Inst Trans
-10.91%
ROA
5.86%
ROE
12.44%
ROIC
6.62%
Gross Margin
44.74%
Oper. Margin
18.74%
Profit Margin
13.27%
SMA20
7.76%
SMA50
13.16%
SMA200
31.36%
Trades
Shs Outstand
42.65M
Shs Float
30.99M
52W High
31.00 -5.26%
52W Low
16.65 76.45%
Volatility
2.99% 3.74%
ATR (14)
1.04
RSI (14)
67.21
Beta
0.94
Rel Volume
0.81
Avg Volume
466.23K
Volume
379,305
Perf Week
3.09%
Perf Month
11.17%
Perf Quarter
40.80%
Perf Half Y
74.10%
Perf YTD
9.67%
Perf Year
11.38%
Perf 3Y
-45.15%
Perf 5Y
37.89%
Perf 10Y
40.32%
Prev Close
28.87
Price
29.37
Change %
1.73%
Consensus
Hold
Avg. Price Target
$24.50
Implied Upside
-16.6%
Analysts10incl. previous ratings
Rating Distribution2 Buy · 7 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 29, 2026Downgrade
BAC logoBBofA Securities
Neutral → Underperform$20-31.9%
May 14, 2026Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight$19-35.3%
May 08, 2026Downgrade
NNeedham
Buy → Hold
Apr 21, 2026Downgrade
JEF logoJJefferies
Buy → Hold$22-25.1%
Dec 09, 2025Initiated
BCS logoBBarclays
Equal Weight$30+2.1%
Aug 12, 2025Upgrade
NNeedham
Hold → Buy$36+22.6%
May 12, 2025Downgrade
JPM logoJJP Morgan
Overweight → Neutral$30+2.1%
Feb 04, 2025Downgrade
PPiper Sandler
Overweight → Neutral$66 → $36+22.6%
Nov 22, 2024Initiated
WFC logoWWells Fargo
Equal Weight$55+87.3%
Mar 05, 2024Initiated
JPM logoJJP Morgan
Overweight$60+104.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PETERS WILLIAM JCFO, EVP & TREASURERNov 04 '26Option Exercise13.0316,000208,480184,707Nov 06 04:17 PM
PETERS WILLIAM JCFO, EVP & TREASURERNov 05 '26Option Exercise17.9911,000197,890179,707Nov 06 04:17 PM
PETERS WILLIAM JCFO, EVP & TREASURERNov 04 '26Sale28.0316,000448,480168,707Nov 06 04:17 PM
PETERS WILLIAM JCFO, EVP & TREASURERNov 05 '26Sale28.9912,631366,189167,076Nov 06 04:17 PM
PETERS WILLIAM JOfficerNov 05 '26Proposed Sale28.9912,631366,189Nov 05 04:05 PM
PETERS WILLIAM JOfficerNov 04 '26Proposed Sale28.0316,000448,480Nov 04 04:09 PM
PETERS WILLIAM JCFO, EVP & TREASURERSep 21 '26Sale25.004,139103,475168,707Sep 23 06:02 PM
PETERS WILLIAM JOfficerSep 21 '26Proposed Sale25.004,139103,475Sep 21 06:37 PM
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 16 '26Option Exercise13.3510,000133,500179,203Sep 17 06:19 PM
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 16 '26Sale23.9410,000239,404169,203Sep 17 06:19 PM
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 02 '26Sale23.633,18775,306169,203Sep 03 07:42 PM
Rong ZhouVice PresidentSep 01 '26Proposed Sale22.0013,187290,114Sep 01 04:25 PM
Floyd PetersenDirectorAug 18 '26Proposed Sale21.0047,101989,121Aug 18 05:56 PM
PRINS RICHARD KDirectorAug 11 '26Sale20.307,973161,85229,625Aug 12 06:14 PM
PETERS WILLIAM JCFO, EVP & TREASURERAug 07 '26Option Exercise19.795,05399,999181,026Aug 11 04:57 PM
PETERS WILLIAM JCFO, EVP & TREASURERAug 07 '26Sale22.488,180183,886172,846Aug 11 04:57 PM
Richard PrinsDirectorAug 11 '26Proposed Sale20.317,973161,932Aug 11 11:53 AM
PETERS WILLIAM JOfficerAug 07 '26Proposed Sale22.488,180183,886Aug 07 04:09 PM
Zhou RongSENIOR EVP, PRODUCTION CENTERDec 17 '25Option Exercise11.339,787110,887147,830Dec 18 05:23 PM
Zhou RongSENIOR EVP, PRODUCTION CENTERDec 17 '25Sale26.209,787256,379138,043Dec 18 05:23 PM
Petersen Floyd F.DirectorDec 12 '25Sale25.922,42662,88871,368Dec 15 05:17 PM
Petersen Floyd F.DirectorDec 11 '25Sale25.691,73744,62073,794Dec 15 05:17 PM
Floyd PetersenDirectorDec 11 '25Proposed Sale80.004,163333,040Dec 11 05:17 PM
Floyd PetersenDirectorDec 10 '25Proposed Sale25.001,73743,425Dec 10 02:40 PM
Rong ZhouOfficerNov 28 '25Proposed Sale25.0020,000500,000Nov 28 01:23 PM
PRINS RICHARD KDirectorNov 25 '25Option Exercise16.694,17969,74839,362Nov 25 07:38 PM
PRINS RICHARD KDirectorNov 25 '25Sale27.104,179113,25335,183Nov 25 07:38 PM
Richard PrinsDirectorNov 25 '25Proposed Sale25.004,179104,475Nov 25 05:05 PM
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredients. It operates through Pharmaceutical Products segment. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
Chairman of the BoardDr. Ziping Luo Ph.D.
Co-FounderDr. Yongfeng Zhang Ph.D.
CFOMr. William J. Peters M.B.A.
Executive VP of SalesMr. Jacob Liawatidewi M.B.A.
Senior EVP of Production & EVP of Scientific AffairsMr. Rong Zhou M.S.